Sinofn Health Sinofn Health

ODM CoQ10: Ubiquinol Vs Ubiquinone

Strategic Manufacturing Insights for Global Nutraceutical Brands

The Scientific Imperative: Ubiquinol vs. Ubiquinone

In the rapidly evolving nutraceutical landscape, the distinction between Coenzyme Q10 (CoQ10) forms is not merely academic—it is a cornerstone of product efficacy and consumer trust. As an ODM partner, SINOFN bridges the gap between complex redox biology and scalable manufacturing.

Ubiquinone (Oxidized State)

Ubiquinone is the traditional, stable, and cost-effective form of CoQ10. It requires enzymatic conversion within the body to Ubiquinol to be utilized. While historically effective, it poses bioavailability challenges, particularly for aging demographics whose enzymatic conversion rates naturally decline.

Ubiquinol (Reduced State)

Ubiquinol is the active, antioxidant-rich form. It offers superior absorption profiles, especially beneficial for cognitive health, cardiovascular support, and mitochondrial energy production. Our R&D division focuses on stabilization technologies to ensure that Ubiquinol maintains its integrity from the production line to the end consumer’s cabinet.

Global Industrial Outlook & China Supply Chain Resilience

China has emerged as the global powerhouse for functional ingredient manufacturing. At SINOFN, we leverage this ecosystem by integrating advanced R&D with manufacturing efficiency. Our strategic location in the Shanghai trading hub, combined with our Tianjin R&D center, allows us to offer:

  • Cost-Efficiency: Optimized raw material sourcing and vertical integration.
  • Supply Chain Stability: Redundant sourcing pathways to mitigate global disruptions.
  • Technological Edge: Utilizing advanced encapsulation to enhance the shelf-life of heat-sensitive ingredients like Ubiquinol.

Science-Driven OEM: The SINOFN Advantage

Founded in 2012, SINOFN Health Co., Ltd. operates under the mentorship of the Chinese Academy of Sciences. We are not just a factory; we are an extension of your R&D team.

53,000㎡Production Facility
25+Patents Held
71+Registered Trademarks

Leadership & Expertise

Our R&D team is led by top-tier experts:

  • Dr. Tan Shengjie: Medical Innovation Director, PhD from Peking University, 15+ years in metabolic disorder formulations.
  • Dr. Zhang Ying: R&D Lead, Associate Researcher at the Chinese Academy of Sciences, specialist in bioactive compound delivery.
  • Hans van Dijk: Formulation Director (Netherlands), EU regulatory specialist.

Manufacturing & Quality Assurance

GMP Production

10+ dedicated lines for softgels, gummies, and powders with annual capacity exceeding 500M units.

QA/QC Center

Rigorous testing via HPLC and GC-MS ensures contaminant screening and microbiological safety.

R&D Prototyping

Pilot-scale development for rapid market entry and bioavailability optimization.

Compliance

ISO22000, HACCP, FSSC 22000, and HALAL certified, meeting international regulatory standards.

Expert FAQ for Supplement Brands

What is the primary difference in manufacturing Ubiquinol vs. Ubiquinone?

Ubiquinol is highly susceptible to oxidation when exposed to light, heat, and air. Our manufacturing processes utilize inert nitrogen blanketing and advanced lipid-matrix encapsulation to stabilize the molecule, a specialized capability that distinguishes our factory.

Can SINOFN support customized R&D for start-ups?

Yes. Our "Science-Driven OEM" model allows for pilot runs and iterative prototyping, helping startups navigate the transition from lab-scale formulation to full-scale commercial production.

How do you ensure global compliance for exports?

We maintain a dedicated regulatory team that tracks international standards (EU, US FDA, ASEAN). Our facilities hold ISO9001, ISO22000, and HALAL certifications, ensuring the documentation required for seamless customs clearance and market entry.